1-3 of 3
Jaymes Holland
Close
Sort by
Journal Articles

Leukocyte Apoptosis and Mitochondrial Dysfunction in β-Thalassemia Patients Treated with Deferasirox or Deferoxamine.

Patrick B. Walter, PhD, John Porter, MD, Patricia Evans, PhD, Janet L. Kwiatkowski, MD, Ellis J. Neufeld, MD, Thomas Coates, MD, Patricia J. Giardina, MD, Robert W. Grady, PhD, Elliott Vichinsky, MD, Nancy F. Olivieri, MD, Felicia Trachtenberg, PhD, Daniele Alberti, MD, Jaymes Holland, PhD, Ellen Fung, PhD, Bruce Ames, PhD, Annie Lui, BS, Paul Harmatz, MD
Journal: Blood
Blood (2007) 110 (11): 2773.
https://doi.org/10.1182/blood.V110.11.2773.2773
Published: 2007
Journal Articles

Pharmacokinetics of Nilotinib in Subjects with Normal or Impaired Hepatic Function.

Jaymes Holland, RPh, Chiaki Tanaka, PhD, Wei Zhou, PhD, Venkat Sethuraman, MS, Douglas M. Heuman, MD, Horst Schran
Journal: Blood
Blood (2007) 110 (11): 2379.
https://doi.org/10.1182/blood.V110.11.2379.2379
Published: 2007
Journal Articles

Control of Oxidant-Stress and Inflammation by Iron Chelators Deferasirox (ICL670) or Deferoxamine in β-Thalassemia: An Ancillary Study of the Novartis CICL670A0107 Trial.

Patrick Walter, PhD, Eric Macklin, PhD, John Porter, MD, Patricia Evans, PhD, Tom Coates, MD, Nancy F. Olivieri, MD, Patricia Giardina, MD, Janet Kwiatkowski, MD, Ellis Neufeld, MD, Bruce Ames, PhD, Jaymes Holland, Peter Marks, MD, Elliott Vichinsky, MD, Paul Harmatz, MD
Journal: Blood
Blood (2005) 106 (11): 3598.
https://doi.org/10.1182/blood.V106.11.3598.3598
Published: 2005